DRUG · Mapped RxNorm record
Dasatinib
Normalized identity: dasatinibView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
NCT00439270
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Docetaxel
Normalized identity: docetaxelView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedStudy of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
DasatinibDRUG · verified · RxNorm: dasatinib
DocetaxelDRUG · verified · RxNorm: docetaxel
Sponsors & collaborators
Bristol-Myers Squibblead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00439270 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.